Oct 2026· Colloids and Surfaces B: Biointerfaces· Vol 269, pp.
116225
· 0 citations· 56 references
Medicine
TL;DR
This work rationally design and construct a novel calixarene derivate CMP, whose upper rim is functionalized with pH-responsive biotin-PEG hydrophilic chains, and lower rim is dually modified with hydrophobic alkyl chains and antitumor pharmacophores.
Abstract
Conventional nanoplatforms often suffer from complicated fabrication, poor structural controllability, insufficient tumor targeting, and unsatisfied therapeutic efficacy. To address these issues, herein we rationally design and construct a novel calix[4]arene derivate CMP, whose upper rim is functionalized with pH-responsive biotin-PEG hydrophilic chains, and lower rim is dually modified with hydrophobic alkyl chains and antitumor pharmacophores. This "all-in-one" supramolecule can not only serve as an excellent supramolecular chemotherapeutic agent itself, but also act as a versatile carrier to co-deliver doxorubicin (DOX) and chlorin e6 (Ce6). The nanoplatform therefore integrates two types of chemotherapeutic modalities and biotin-targeted photodynamic therapy for multi-modal tumor treatment. Notably, in vivo experiments demonstrate that the resultant DOX@CMP@Ce6 nanosystem achieves a 90.5% tumor growth inhibition rate, while displaying biotin-mediated tumor tropism, excellent biocompatibility, and robust triple-modality combinatorial therapeutic effects. Collectively, this work provides key insights into the rational construction of multifunctional supramolecular platforms, reinforcing the broad prospects of calixarene derivatives for nanomedical applications.
Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to chemotherapy due to dense stromal barriers. Although gemcitabine remains the standard treatment, its efficacy is limited. Combining it with the pseudopeptide N6L has shown synergistic effects, but administering them individually in biological systems pose...
L. Larue, Blandine Brissault, Cléa Chesneau et al.· Biomacromolecules· 0 citations
INTRODUCTION
Traditional tumor therapies have limited efficacy, leading to a high mortality rate. Although immunotherapy holds considerable therapeutic promise, clinical immunotherapy for solid tumors only elicits durable responses in a minority of patients. This limitation is largely attributed to the highly immunosup...
Hui-Xi Yi, Chao Jiang, Zheng-Yin Pan et al.· Journal of Advanced Research· 0 citations
Photothermal therapy (PTT) offers the advantages of noninvasiveness and high selectivity, while chemotherapy shows potent antitumor activity. However, their standalone applications are limited by insufficient photothermal ablation efficacy and chemotherapeutic resistance, respectively. To address these challenges, we...
Yu Jiang, Chen Guo, Zhen-Kun Sun et al.· Molecular Pharmaceutics· 0 citations
Porphyrin-based photosensitizers (PSs) are among the most widely explored agents for photodynamic therapy (PDT), yet their clinical translation is severely limited by poor biocompatibility, aggregation-induced quenching, insufficient tumor selectivity, and the intrinsic reactive oxygen species (ROS) resistance of cance...
Yi-Hui Ai, Chong-Zhi Wu, Zhi-Yao Li et al.· Small· 0 citations
This review comprehensively examines recent advancements in dendrimer-mediated delivery systems, elucidating their capacity to optimize solubility, enhance bioavailability, and facilitate the site-specific targeting of therapeutic payloads and offers crucial insights into overcoming translational bottlenecks in targete...
Smit Saha, Solagiri Mouli, Suresh Mamidi et al.· Russian journal of bioorgani...· 0 citations
The clinical efficacy of vincristine (VIN) is often restricted by dose-limiting toxicity, poor tumor selectivity, and rapid systemic distribution. Another biomolecule, thymoquinone (TQ), has negligible toxicity, but poor aqueous solubility and limited bioavailability hamper its use in cancer therapy. In this study, a f...
S. Khan, Muhammad Rafiq, A. Raouf et al.· Colloids and Surfaces B: Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.